Huntington’s Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Symptomatic Treatment, Disease-Modifying Therapies), By Region (North America, Europe, APAC, Latin America, MEA), And Segment Forecasts, 2022 - 2030
This report can be delivered to the clients within 72 Business Hours
Huntington’s Disease Treatment Market Growth & Trends
The global Huntington’s disease treatment market size is expected to reach USD 1.8 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 19.6% from 2022 to 2030. This growth is due to high R&D investments for new product development, research collaboration, and the high HD burden in western countries. Huntington's disease is a rare inherited neurodegenerative disease that affects several generations. It affects people between the ages of 30 and 50, impairing their capacity to work, care for their families, and, eventually, complete daily tasks.
The prevalence varies by more than ten-fold between geographical locations, which can be related to variations in case ascertainment and diagnostic criteria. The prevalence varies by more than ten-fold between geographical locations, which can be related to variations in case ascertainment and diagnostic criteria. As a result, the prevalence of enlarged repetitions in the general population may be greater than expected. The Asian population has consistently had a lower prevalence, while Europe, North America, and Australia have a higher prevalence.
The key players, such as Neurocrine Biosciences, Inc. and Azevan Pharmaceuticals, Inc., are focusing on research and development of symptomatic therapies for HD. Azevan Pharmaceuticals is developing SRX246 as an experimental drug to treat neuropsychiatric symptoms in Huntington's disease. SRX246 is a drug that works by blocking the vasopressin 1a (V1a) receptor in the brain. In the neurological system, V1a receptor is the major vasopressin receptor. SRX246 works by inhibiting the V1a receptor, restricting vasopressin from attaching to the receptor, and generating irritable and aggressive behavior, which is seen in Huntington's disease patients.
However, currently approved drugs provide symptomatic and palliative care and do not target the underlying cause of the disease. While medications can decrease the severity of symptoms, they are often associated with adverse effects such as somnolence, gait issues, dysphagia, and apathy, which can have serious impacts on a patient’s quality of life. Given the lack of a cure for the disease, it is critical to evaluate how Health-related Quality of Life (HRQOL) is affected in these patients. HD patients in early to middle stages of the disease need coordinated multidisciplinary healthcare services, including assessment of cognitive function and counseling.
Drug development for HD has faced significant obstacles as several therapies have failed to demonstrate efficacy or were associated with significant toxicity. Vaccinex Inc.'s phase II trial of Pepinemab failed to satisfy pre-specified co-primary endpoints in patients with early manifest and prodromal HD, in September 2020. The two co-primary endpoints—a family of two cognitive evaluations from the Huntington's disease Cognitive Assessment Battery and Clinical Global Impression of Change (CGIC)—did not attain statistical significance in the early manifestation population in the SIGNAL study.
Huntington’s Disease Treatment Market Report Highlights
Huntington’s Disease Treatment Market Growth & Trends
The global Huntington’s disease treatment market size is expected to reach USD 1.8 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 19.6% from 2022 to 2030. This growth is due to high R&D investments for new product development, research collaboration, and the high HD burden in western countries. Huntington's disease is a rare inherited neurodegenerative disease that affects several generations. It affects people between the ages of 30 and 50, impairing their capacity to work, care for their families, and, eventually, complete daily tasks.
The prevalence varies by more than ten-fold between geographical locations, which can be related to variations in case ascertainment and diagnostic criteria. The prevalence varies by more than ten-fold between geographical locations, which can be related to variations in case ascertainment and diagnostic criteria. As a result, the prevalence of enlarged repetitions in the general population may be greater than expected. The Asian population has consistently had a lower prevalence, while Europe, North America, and Australia have a higher prevalence.
The key players, such as Neurocrine Biosciences, Inc. and Azevan Pharmaceuticals, Inc., are focusing on research and development of symptomatic therapies for HD. Azevan Pharmaceuticals is developing SRX246 as an experimental drug to treat neuropsychiatric symptoms in Huntington's disease. SRX246 is a drug that works by blocking the vasopressin 1a (V1a) receptor in the brain. In the neurological system, V1a receptor is the major vasopressin receptor. SRX246 works by inhibiting the V1a receptor, restricting vasopressin from attaching to the receptor, and generating irritable and aggressive behavior, which is seen in Huntington's disease patients.
However, currently approved drugs provide symptomatic and palliative care and do not target the underlying cause of the disease. While medications can decrease the severity of symptoms, they are often associated with adverse effects such as somnolence, gait issues, dysphagia, and apathy, which can have serious impacts on a patient’s quality of life. Given the lack of a cure for the disease, it is critical to evaluate how Health-related Quality of Life (HRQOL) is affected in these patients. HD patients in early to middle stages of the disease need coordinated multidisciplinary healthcare services, including assessment of cognitive function and counseling.
Drug development for HD has faced significant obstacles as several therapies have failed to demonstrate efficacy or were associated with significant toxicity. Vaccinex Inc.'s phase II trial of Pepinemab failed to satisfy pre-specified co-primary endpoints in patients with early manifest and prodromal HD, in September 2020. The two co-primary endpoints—a family of two cognitive evaluations from the Huntington's disease Cognitive Assessment Battery and Clinical Global Impression of Change (CGIC)—did not attain statistical significance in the early manifestation population in the SIGNAL study.
Huntington’s Disease Treatment Market Report Highlights
- The symptomatic treatment segment accounted for the largest revenue share in 2021 owing to the product availability and patent protection. Disease-modifying therapies is anticipated to be the fastest-growing segment over the forecast years due to the entry of SAGE-718, and Cellavita-HD
- Companies are now focusing on the development of treatments that can be injected directly into the brain to directly inhibit the formation of mutant HTT protein, instead of targeting the mutant protein
- Drugs with novel targets in early-phase development include Cellavita and Azidus Brazil’s Cellavita HD (stem cell therapy), Sangamo Therapeutics, Inc. mHTT ZFP (zinc finger protein), and UniQure’s AMT-130 (gene therapy)
- North America held the highest revenue share in 2021 and is expected to dominate the market over the forecast period due to better reimbursement facilities and the high burden of HD in the U.S. and Canada
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market Segmentation and Scope
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective
1.10.2 Objective
1.10.3 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
CHAPTER 3 HUNTINGTON’S DISEASE TREATMENT MARKET VARIABLES, TRENDS, AND SCOPE
3.1 Parent Market Outlook
3.1.1 Central Nervous System Therapeutics Market
3.2 Penetration and Growth Prospect Mapping
3.3 Regulatory & Reimbursement Scenario
3.4 Market Driver Analysis
3.4.1 Strong Product Pipeline
3.4.2 Disease Burden Of Huntington’s In Developed Countries
3.5 Market Restraint Analysis
3.5.1 Significant Challenges And Unmet Needs In Huntington’s Disease Treatment
3.5.2 High Failure Rate In Clinical Trials
3.6 Major Deals and Strategic Alliances
3.7 Pipeline Analysis
3.8 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.9 Industry Analysis – Porter’s
CHAPTER 4 HUNTINGTON’S DISEASE TREATMENT MARKET: COMPETITIVE ANALYSIS
4.1 Recent Developments and Impact Analysis, by Key Market Participants
4.1.1 New Product Launches
4.1.2 Mergers And Acquisitions
4.1.3 Partnerships And Strategic Collaboration
4.1.4 Conferences And Campaigns
4.2 Company Categorization
4.2.1 Innovators
4.2.2 Market Leaders
4.2.3 Heat Map Analysis
4.3 Vendor Landscape
4.3.1 List Of Key Distributors And Channel Partners
4.3.2 Key Customers
4.4 Key Company Market Share Analysis, 2021
4.5 Public Companies
4.5.1 Company Market Position Analysis
4.5.2 Competitive Dashboard Analysis
4.5.2.1 Market Differentiators
4.6 Private Companies
4.6.1 List Of Key Emerging Companies
4.6.2 Regional Network Map
CHAPTER 5 HUNTINGTON’S DISEASE TREATMENT MARKET: SEGMENT ANALYSIS, BY TREATMENT, 2017 - 2030 (USD MILLION)
5.1 Huntington’s Disease Treatment Market: Treatment Movement Analysis
5.2 Symptomatic Treatment
5.2.1 Symptomatic Treatment Market, 2017 - 2030 (USD Million)
5.3 Disease-Modifying Therapies
5.3.1 Disease-Modifying Therapies Market, 2017 - 2030 (USD Million)
CHAPTER 6 HUNTINGTON’S DISEASE TREATMENT MARKET: SEGMENT ANALYSIS, BY REGION, 2017 - 2030 (USD MILLION)
6.1 Definition & Scope
6.2 Regional Market Share Analysis, 2021 & 2030
6.3 Regional Market Snapshot
6.4 Market Size, & Forecasts, Revenue and Trend Analysis, 2021 to 2030
6.4.1 North America
6.4.1.1 North America market estimates and forecast, 2017 - 2028 (USD Million)
6.4.1.2 U.S.
6.4.1.2.1 U.S. Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.1.3 Canada
6.4.1.3.1 Canada Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.2 Europe
6.4.2.1 Europe Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.2.2 U.K.
6.4.2.2.1 U.K. Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.2.3 Germany
6.4.2.3.1 Germany Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.2.4 Spain
6.4.2.4.1 Spain Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.2.5 France
6.4.2.5.1 France Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.2.6 Italy
6.4.2.6.1 Italy Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.3 Asia Pacific
6.4.3.1 Asia Pacific Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.3.2 Japan
6.4.3.2.1 Japan Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.3.3 China
6.4.3.3.1 China Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.3.4 India
6.4.3.4.1 India Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.3.5 South Korea
6.4.3.5.1 South Korea Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.3.6 Australia
6.4.3.6.1 Australia Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.4 Latin America
6.4.4.1 Latin America Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.4.2 Brazil
6.4.4.2.1 Brazil Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.4.3 Mexico
6.4.4.3.1 Mexico Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.4.4 Argentina
6.4.4.4.1 Argentina Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.5 MEA
6.4.5.1 MEA Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.5.2 South Africa
6.4.5.2.1 South Africa Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.5.3 Saudi Arabia
6.4.5.3.1 Saudi Arabia Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.5.4 UAE
6.4.5.4.1 UAE Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
CHAPTER 7 HUNTINGTON’S DISEASE TREATMENT MARKET: COMPANY PROFILES
7.1 H. Lundbeck A/S
7.1.1 Company Overview
7.1.2 Financial Performance
7.1.3 Product Benchmarking
7.1.4 Strategic Initiatives
7.2 Teva Pharmaceutical Industries Ltd.
7.2.1 Company Overview
7.2.2 Financial Performance
7.2.3 Product Benchmarking
7.2.4 Strategic Initiatives
7.3 Bausch Health Companies Inc.
7.3.1 Company Overview
7.3.2 Financial Performance
7.3.3 Product Benchmarking
7.3.4 Strategic Initiatives
7.4 Hetero
7.4.1 Company Overview
7.4.2 Financial Performance
7.4.3 Product Benchmarking
7.4.4 Strategic Initiatives
7.5 Lupin
7.5.1 Company Overview
7.5.2 Financial Performance
7.5.3 Product Benchmarking
7.5.4 Strategic Initiatives
7.6 Hikma Pharmaceuticals PLC
7.6.1 Company Overview
7.6.2 Financial Performance
7.6.3 Product Benchmarking
7.6.4 Strategic Initiatives
7.7 Dr. Reddy’s Laboratories Ltd.
7.7.1 Company Overview
7.7.2 Financial Performance
7.7.3 Product Benchmarking
7.7.4 Strategic Initiatives
7.8 Sun Pharmaceutical Industries Ltd.
7.8.1 Company Overview
7.8.2 Financial Performance
7.8.3 Product Benchmarking
7.8.4 Strategic Initiatives
1.1 Market Segmentation and Scope
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective
1.10.2 Objective
1.10.3 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
CHAPTER 3 HUNTINGTON’S DISEASE TREATMENT MARKET VARIABLES, TRENDS, AND SCOPE
3.1 Parent Market Outlook
3.1.1 Central Nervous System Therapeutics Market
3.2 Penetration and Growth Prospect Mapping
3.3 Regulatory & Reimbursement Scenario
3.4 Market Driver Analysis
3.4.1 Strong Product Pipeline
3.4.2 Disease Burden Of Huntington’s In Developed Countries
3.5 Market Restraint Analysis
3.5.1 Significant Challenges And Unmet Needs In Huntington’s Disease Treatment
3.5.2 High Failure Rate In Clinical Trials
3.6 Major Deals and Strategic Alliances
3.7 Pipeline Analysis
3.8 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.9 Industry Analysis – Porter’s
CHAPTER 4 HUNTINGTON’S DISEASE TREATMENT MARKET: COMPETITIVE ANALYSIS
4.1 Recent Developments and Impact Analysis, by Key Market Participants
4.1.1 New Product Launches
4.1.2 Mergers And Acquisitions
4.1.3 Partnerships And Strategic Collaboration
4.1.4 Conferences And Campaigns
4.2 Company Categorization
4.2.1 Innovators
4.2.2 Market Leaders
4.2.3 Heat Map Analysis
4.3 Vendor Landscape
4.3.1 List Of Key Distributors And Channel Partners
4.3.2 Key Customers
4.4 Key Company Market Share Analysis, 2021
4.5 Public Companies
4.5.1 Company Market Position Analysis
4.5.2 Competitive Dashboard Analysis
4.5.2.1 Market Differentiators
4.6 Private Companies
4.6.1 List Of Key Emerging Companies
4.6.2 Regional Network Map
CHAPTER 5 HUNTINGTON’S DISEASE TREATMENT MARKET: SEGMENT ANALYSIS, BY TREATMENT, 2017 - 2030 (USD MILLION)
5.1 Huntington’s Disease Treatment Market: Treatment Movement Analysis
5.2 Symptomatic Treatment
5.2.1 Symptomatic Treatment Market, 2017 - 2030 (USD Million)
5.3 Disease-Modifying Therapies
5.3.1 Disease-Modifying Therapies Market, 2017 - 2030 (USD Million)
CHAPTER 6 HUNTINGTON’S DISEASE TREATMENT MARKET: SEGMENT ANALYSIS, BY REGION, 2017 - 2030 (USD MILLION)
6.1 Definition & Scope
6.2 Regional Market Share Analysis, 2021 & 2030
6.3 Regional Market Snapshot
6.4 Market Size, & Forecasts, Revenue and Trend Analysis, 2021 to 2030
6.4.1 North America
6.4.1.1 North America market estimates and forecast, 2017 - 2028 (USD Million)
6.4.1.2 U.S.
6.4.1.2.1 U.S. Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.1.3 Canada
6.4.1.3.1 Canada Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.2 Europe
6.4.2.1 Europe Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.2.2 U.K.
6.4.2.2.1 U.K. Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.2.3 Germany
6.4.2.3.1 Germany Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.2.4 Spain
6.4.2.4.1 Spain Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.2.5 France
6.4.2.5.1 France Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.2.6 Italy
6.4.2.6.1 Italy Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.3 Asia Pacific
6.4.3.1 Asia Pacific Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.3.2 Japan
6.4.3.2.1 Japan Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.3.3 China
6.4.3.3.1 China Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.3.4 India
6.4.3.4.1 India Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.3.5 South Korea
6.4.3.5.1 South Korea Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.3.6 Australia
6.4.3.6.1 Australia Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.4 Latin America
6.4.4.1 Latin America Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.4.2 Brazil
6.4.4.2.1 Brazil Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.4.3 Mexico
6.4.4.3.1 Mexico Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.4.4 Argentina
6.4.4.4.1 Argentina Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.5 MEA
6.4.5.1 MEA Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.5.2 South Africa
6.4.5.2.1 South Africa Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.5.3 Saudi Arabia
6.4.5.3.1 Saudi Arabia Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
6.4.5.4 UAE
6.4.5.4.1 UAE Huntington’s Disease Treatment market, 2017 - 2030 (USD Million)
CHAPTER 7 HUNTINGTON’S DISEASE TREATMENT MARKET: COMPANY PROFILES
7.1 H. Lundbeck A/S
7.1.1 Company Overview
7.1.2 Financial Performance
7.1.3 Product Benchmarking
7.1.4 Strategic Initiatives
7.2 Teva Pharmaceutical Industries Ltd.
7.2.1 Company Overview
7.2.2 Financial Performance
7.2.3 Product Benchmarking
7.2.4 Strategic Initiatives
7.3 Bausch Health Companies Inc.
7.3.1 Company Overview
7.3.2 Financial Performance
7.3.3 Product Benchmarking
7.3.4 Strategic Initiatives
7.4 Hetero
7.4.1 Company Overview
7.4.2 Financial Performance
7.4.3 Product Benchmarking
7.4.4 Strategic Initiatives
7.5 Lupin
7.5.1 Company Overview
7.5.2 Financial Performance
7.5.3 Product Benchmarking
7.5.4 Strategic Initiatives
7.6 Hikma Pharmaceuticals PLC
7.6.1 Company Overview
7.6.2 Financial Performance
7.6.3 Product Benchmarking
7.6.4 Strategic Initiatives
7.7 Dr. Reddy’s Laboratories Ltd.
7.7.1 Company Overview
7.7.2 Financial Performance
7.7.3 Product Benchmarking
7.7.4 Strategic Initiatives
7.8 Sun Pharmaceutical Industries Ltd.
7.8.1 Company Overview
7.8.2 Financial Performance
7.8.3 Product Benchmarking
7.8.4 Strategic Initiatives
LIST OF TABLES
TABLE 1 List of secondary sources
TABLE 2 List of Abbreviations
TABLE 3 North America Huntington’s Disease Treatment market estimates and forecasts, by country, 2017 - 2030 (USD Million)
TABLE 4 North America Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 5 U.S. Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 6 Canada Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 7 Europe Huntington’s Disease Treatment market estimates and forecasts, by country, 2017 - 2030 (USD Million)
TABLE 8 Europe Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 9 U.K. Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 62028 (USD Million)
TABLE 10 Germany Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 11 France Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 12 Italy Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 13 Spain Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 14 Asia Pacific Huntington’s Disease Treatment market estimates and forecasts, by country, 2017 - 2030 (USD Million)
TABLE 15 Asia Pacific Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 16 Japan Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 17 China Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 18 India Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 19 Australia Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 20 South Korea Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 21 Latin America Huntington’s Disease Treatment market estimates and forecasts, by country, 2017 - 2030 (USD Million)
TABLE 22 Latin America Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 23 Brazil Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 24 Mexico Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 25 Argentina Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 26 MEA Huntington’s Disease Treatment market estimates and forecasts, by country, 2017 - 2030 (USD Million)
TABLE 27 MEA Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 28 South Africa Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 30 Saudi Arabia Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 31 UAE Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 32 List of key distributors
TABLE 1 List of secondary sources
TABLE 2 List of Abbreviations
TABLE 3 North America Huntington’s Disease Treatment market estimates and forecasts, by country, 2017 - 2030 (USD Million)
TABLE 4 North America Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 5 U.S. Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 6 Canada Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 7 Europe Huntington’s Disease Treatment market estimates and forecasts, by country, 2017 - 2030 (USD Million)
TABLE 8 Europe Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 9 U.K. Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 62028 (USD Million)
TABLE 10 Germany Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 11 France Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 12 Italy Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 13 Spain Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 14 Asia Pacific Huntington’s Disease Treatment market estimates and forecasts, by country, 2017 - 2030 (USD Million)
TABLE 15 Asia Pacific Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 16 Japan Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 17 China Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 18 India Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 19 Australia Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 20 South Korea Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 21 Latin America Huntington’s Disease Treatment market estimates and forecasts, by country, 2017 - 2030 (USD Million)
TABLE 22 Latin America Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 23 Brazil Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 24 Mexico Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 25 Argentina Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 26 MEA Huntington’s Disease Treatment market estimates and forecasts, by country, 2017 - 2030 (USD Million)
TABLE 27 MEA Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 28 South Africa Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 30 Saudi Arabia Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 31 UAE Huntington’s Disease Treatment market estimates and forecasts, by treatment, 2017 - 2030 (USD Million)
TABLE 32 List of key distributors
LIST OF FIGURES
FIG. 1 Huntington’s disease treatment market segmentation
FIG. 2 Market research process
FIG. 3 Information procurement
FIG. 4 Primary research pattern
FIG. 5 Market research approaches
FIG. 6 Value-chain-based sizing & forecasting
FIG. 7 QFD modeling for market share assessment
FIG. 8 Market formulation & validation
FIG. 9 Market outlook (2021)
FIG. 10 Penetration and growth prospect mapping
FIG. 11 Huntington’s disease treatment market driver impact
FIG. 12 Huntington’s disease treatment market restraint impact
FIG. 13 Major deals and strategic alliances
FIG. 14 SWOT analysis, by factor (political & legal, economic, and technological)
FIG. 15 Porter’s five forces analysis
FIG. 16 Heat map analysis
FIG. 17 Company market position analysis (2021)
FIG. 18 Company market position analysis (2021)
FIG. 19 Company market position analysis (2021)
FIG. 20 Market differentiators
FIG. 21 Regional network map
FIG. 22 Huntington’s disease treatment market treatment outlook: Key takeaways
FIG. 23 Huntington’s disease treatment market: Treatment movement analysis
FIG. 24 Symptomatic treatment market, 2017 - 2030 (USD million)
FIG. 25 Disease-modifying therapies market, 2017 - 2030 (USD million)
FIG. 26 Regional outlook, 2021& 2030
FIG. 27 Regional marketplace: Key takeaways
FIG. 28 North America
FIG. 29 North America Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 30 U.S.
FIG. 31 U.S. Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 32 Canada
FIG. 33 Canada Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 34 Europe
FIG. 35 Europe Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 36 U.K.
FIG. 37 U.K. Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 38 Germany
FIG. 39 Germany Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 40 Spain
FIG. 41 Spain Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 42 France
FIG. 43 France Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 44 Italy
FIG. 45 Italy Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 46 Asia Pacific
FIG. 47 Asia Pacific Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 48 Japan
FIG. 49 Japan Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 50 China
FIG. 51 China Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 52 India
FIG. 53 India Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 54 South Korea
FIG. 55 South Korea Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 56 Australia
FIG. 57 Australia Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 58 Latin America
FIG. 59 Latin America Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 60 Brazil
FIG. 61 Brazil Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 62 Mexico
FIG. 63 Mexico Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 64 Argentina
FIG. 65 Argentina Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 66 Middle East and Africa
FIG. 67 MEA Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 68 South Africa
FIG. 69 South Africa Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 70 Saudi Arabia
FIG. 71 Saudi Arabia Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 72 UAE
FIG. 73 UAE Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 1 Huntington’s disease treatment market segmentation
FIG. 2 Market research process
FIG. 3 Information procurement
FIG. 4 Primary research pattern
FIG. 5 Market research approaches
FIG. 6 Value-chain-based sizing & forecasting
FIG. 7 QFD modeling for market share assessment
FIG. 8 Market formulation & validation
FIG. 9 Market outlook (2021)
FIG. 10 Penetration and growth prospect mapping
FIG. 11 Huntington’s disease treatment market driver impact
FIG. 12 Huntington’s disease treatment market restraint impact
FIG. 13 Major deals and strategic alliances
FIG. 14 SWOT analysis, by factor (political & legal, economic, and technological)
FIG. 15 Porter’s five forces analysis
FIG. 16 Heat map analysis
FIG. 17 Company market position analysis (2021)
FIG. 18 Company market position analysis (2021)
FIG. 19 Company market position analysis (2021)
FIG. 20 Market differentiators
FIG. 21 Regional network map
FIG. 22 Huntington’s disease treatment market treatment outlook: Key takeaways
FIG. 23 Huntington’s disease treatment market: Treatment movement analysis
FIG. 24 Symptomatic treatment market, 2017 - 2030 (USD million)
FIG. 25 Disease-modifying therapies market, 2017 - 2030 (USD million)
FIG. 26 Regional outlook, 2021& 2030
FIG. 27 Regional marketplace: Key takeaways
FIG. 28 North America
FIG. 29 North America Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 30 U.S.
FIG. 31 U.S. Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 32 Canada
FIG. 33 Canada Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 34 Europe
FIG. 35 Europe Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 36 U.K.
FIG. 37 U.K. Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 38 Germany
FIG. 39 Germany Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 40 Spain
FIG. 41 Spain Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 42 France
FIG. 43 France Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 44 Italy
FIG. 45 Italy Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 46 Asia Pacific
FIG. 47 Asia Pacific Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 48 Japan
FIG. 49 Japan Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 50 China
FIG. 51 China Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 52 India
FIG. 53 India Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 54 South Korea
FIG. 55 South Korea Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 56 Australia
FIG. 57 Australia Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 58 Latin America
FIG. 59 Latin America Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 60 Brazil
FIG. 61 Brazil Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 62 Mexico
FIG. 63 Mexico Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 64 Argentina
FIG. 65 Argentina Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 66 Middle East and Africa
FIG. 67 MEA Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 68 South Africa
FIG. 69 South Africa Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 70 Saudi Arabia
FIG. 71 Saudi Arabia Huntington’s disease treatment market, 2017 - 2030 (USD Million)
FIG. 72 UAE
FIG. 73 UAE Huntington’s disease treatment market, 2017 - 2030 (USD Million)
